Read the Conversation
Conversation highlights:
- Country-tailored growth strategy: While aligning under a unified EMEA vision, QIAGEN is increasingly deploying country-specific strategies. These include driving TB, meningitis, and syndromic testing programs while scaling our regional presence (notably in Saudi Arabia), and adapting to fast-evolving markets like the UAE.
- Government and ecosystem focus: Stronger engagement with Ministries of Health, MOUs, and prevention/screening programs is central, alongside advocacy for greater research funding and deeper local innovation across the Gulf and Levant.
- Data and precision medicine transformation: Over the past decade, QIAGEN has expanded regional genomic and bioinformatics datasets to reflect Middle Eastern and African populations, enabling more precise diagnostics and advancing ambitions such as personalized cancer monitoring.
- Upgraded distributor partnerships: QIAGEN has developed its partnerships to align strategically—building dedicated commercial, marketing, and medical teams within distributors, increasing mutual commitment, and professionalizing execution across markets.
- Innovation-driven culture and future growth: Reflecting on nearly a decade at QIAGEN, Simona highlights the company’s scientific mindset, rapid business expansion in emerging markets, and continued focus on translating technological innovation into stronger commercial impact and regional talent development – all with the goal to improve the lives of patients around the world, and in particular in the Gulf and Levant.
EF: What are your current priorities for the EMEA region, and what key challenges and opportunities are you addressing?
SG: Our unified EMEA strategy centers on deploying innovative technologies while building deeper governmental partnerships to advance national health objectives. We've signed memorandums of understanding with health ministries and institutions across the region, focusing on prevention programs, screening initiatives, and precision medicine implementation.
Each market requires tailored approaches. In Qatar, we're pursuing precision medicine with highly customized strategies. Saudi Arabia presents geographical challenges, but the Ministry of Health's laboratory coverage creates significant opportunities. We're establishing regional presence beyond major cities like Riyadh and Jeddah to ensure comprehensive coverage through our Local Commercial Partners.
After years of building a foundation, we're now scaling through demand generation and physician advocacy. The UAE exemplifies rapid market evolution, and Dubai's constantly changing landscape mirrors the transformation of healthcare. Emirates operates heavily on digital channels, leading us to explore unconventional advocacy platforms like TikTok for scientific audiences.
Our commitment to sustainable growth now enables country-specific investment in resources. Previously, smaller operations required general approaches, but our expanding partnerships and stronger market position enable focused strategies tailored to each nation's regulatory environment and healthcare priorities.
EF: How has data infrastructure evolved across the region, and how do you ensure it benefits patients?
SG: Over the last 10 years, we have addressed critical gaps in regional bioinformatics data; medicines developed in Europe for African markets often failed due to a lack of ethnic diversity in datasets. Middle Eastern clinicians consistently asked why regional genetic data weren't available for their populations.
We have systematically addressed this by generating comprehensive data from the Middle East and Africa over the past decade. Major NGS instrumentation providers have established significant operations in Africa, while training centers and data facilities have emerged across the Middle East.
This regional data collection, conducted in accordance with local compliance and GDPR guidelines, enables superior clinical decision-making. National genomic programs across the Middle East provide unprecedented insights into disease patterns, pathways, and biomarkers.
The future points toward personalized monitoring; every cancer patient should have individualized testing for ongoing surveillance. While this concept might seem impossible from a corporate perspective, it represents the logical evolution of precision medicine. We believe that those who implement this approach properly have the best opportunities to achieve optimal patient outcomes.
EF: How has your partnership strategy evolved, and what criteria guide partner selection?
SG: We've fundamentally redesigned our Middle Eastern partnerships over the past five years to align with our growth strategy. Success requires partners who share our ambition. If QIAGEN aims for aggressive expansion, we need locally ambitious partners with relevant portfolio expertise.
Our partnerships have evolved into dedicated relationships where distributors allocate specific teams exclusively to our business. These professionals receive training equivalent to that of our employees in commercial excellence, education, and marketing activities. This represents a complete transformation in the scope and effectiveness of the partnership.
The financial dynamics have shifted dramatically. When you represent only about 5% of a partner's annual turnover, you receive limited attention. Now, as we represent about 25-30% of their annual business, we've achieved strategic importance, and that transforms the quality of the relationship.
Market evolution demands professional partner selection. Both sides now evaluate philosophical alignment and business compatibility. We've stabilized our representation network, allowing focus on business development rather than partner research.
Successful partnerships require investment in three critical departments: commercial sales teams, marketing, and medical affairs. Partners demonstrating commitment across all three areas consistently deliver superior returns and sustainable growth.
EF: How do you balance priorities across EMEA's diverse markets with varying GDP levels, currencies, and regulatory frameworks?
SG: EMEA represents the most challenging and exciting region to manage, presenting daily complexity across economic, regulatory, and cultural dimensions. The strategy requires balancing standardization opportunities with market-specific customization needs.
We draft a regional vision and strategy, then rely on strong local leadership for implementation. Every country now has dedicated country marketing functions, a structure I insisted upon, to translate corporate vision into localized execution. This approach acknowledges that certain standardization efforts simply aren't feasible across such diversity.
The portfolio complexity varies significantly. Some products require minimal strategic variation, while others demand more distinct approaches. Digital PCR exemplifies this challenge.
Our approach centers on user value-driven strategies. We analyze which customers value specific attributes, then develop targeted approaches. Sometimes one strategy suffices; other portfolios require fifteen variations to achieve market penetration. The key lies in understanding customer segments and delivering relevant value propositions rather than applying universal solutions to diverse markets.
EF: Reflecting on nearly ten years at QIAGEN, what key moments and achievements stand out?
SG: The caliber of people at QIAGEN consistently impresses me; highly educated scientific advocates for life science, research, and healthcare. This quality remains constant across every new initiative and expansion over the last decade, and my view is that this will only improve step by step in the future.
Our business transformation has been remarkable. Middle East, Africa, and Eastern Europe operations have grown threefold since my arrival. We've professionalized customer services and commercial partner relationships while maintaining our improvement-driven culture that pushes daily excellence.
QIAGEN's focus on translating innovations from research and life science into diagnostics creates a unique mindset. We continuously discover new applications, then determine routine implementation pathways. This innovation obsession permeates our entire portfolio approach.
The challenge lies in supporting colleagues to maintain their technical and innovation obsession while providing enhanced commercial tools. Many team members bring scientific backgrounds, and we must effectively transform technical knowledge into commercial success.
QIAGEN possesses tremendous growth opportunities. I approach business by identifying possibilities rather than obstacles; what we can do bigger, better, and more effectively. This perspective applies to our portfolios and team member development, driving continuous advancement in our capabilities and market impact.
EF: What final message would you share about the Gulf region's healthcare future?
SG: The Gulf region represents an exciting healthcare frontier requiring collective advocacy for increased research funding. Enhanced investment will enable the Middle East to transition from technology adoption to indigenous innovation, fostering regional scientific leadership.
Our regional commitment includes expanding activities through local manufacturing and other localization initiatives. We're focused on identifying and developing the best regional talent for corporate advancement, creating and developing comprehensive ecosystems.
Success requires functional integration across all ecosystem components, research funding, local innovation capacity, manufacturing capabilities, and talent development. This holistic approach builds sustainable healthcare infrastructure rather than dependency on external solutions.
The region's potential extends beyond current achievements. With proper investment and strategic development, the Gulf can become a global healthcare innovation hub rather than simply a market for international products. This transformation demands coordinated effort from industry, government, and academic institutions working toward shared objectives.
